
- /
- Supported exchanges
- / F
- / 0PT.F
Prothena Corporation plc (0PT F) stock market data APIs
Prothena Corporation plc Financial Data Overview
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease; and PRX019 for the treatment of neurogenerative diseases, as well as TDP-43 for the treatment of amyotrophic lateral sclerosis. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. The company was incorporated in 2012 and is based in Dublin, Ireland.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Prothena Corporation plc data using free add-ons & libraries
Get Prothena Corporation plc Fundamental Data
Prothena Corporation plc Fundamental data includes:
- Net Revenue: 133 M
- EBITDA: -167 231 008
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-02-10
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Prothena Corporation plc News

CHMP to Delay Nod on Biogen (BIIB), Eisai's Alzheimer's Drug
Biogen BIIB and partner Eisai recently announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has delayed the decision on their Alzheimer’s dise...


Prothena Appoints David Ford to Newly Created Chief People Officer Position
David Ford, Chief People Officer, Prothena (Photo: Business Wire) DUBLIN, March 04, 2024--(BUSINESS WIRE)--Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a r...

Prothena Announces Appointment of Daniel G. Welch as Director and Chair Designate
Daniel G. Welch (Photo: Business Wire) DUBLIN, February 21, 2024--(BUSINESS WIRE)--Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of invest...

Prothena Full Year 2023 Earnings: Beats Expectations
Prothena (NASDAQ:PRTA) Full Year 2023 Results Key Financial Results Revenue: US$91.4m (up 70% from FY 2022). Net loss: US$147.0m (loss widened by 26% from FY 2022). US$2.76 loss per share (further d...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.